The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ICLR | -32.06% | -0.9% | -0.18% | +2,939% |
| S&P | +14.5% | +93.32% | +14.09% | +504% |
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.
These companies strive to bring down the cost of developing new therapies.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.02B | -4.8% |
| Gross Profit | $463.88M | -2.7% |
| Gross Margin | 22.99% | 0.5% |
| Market Cap | $11.75B | -54.7% |
| Market Cap / Employee | $0.29M | -53.3% |
| Employees | 39.9K | 0.0% |
| Net Income | $182.97M | 24.5% |
| EBITDA | $366.19M | -16.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $390.40M | -22.9% |
| Accounts Receivable | $2.61B | -6.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.52B | -1.0% |
| Short Term Debt | $29.76M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.73% | 0.5% |
| Return On Invested Capital | 6.08% | -3.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $127.55M | -29.3% |
| Operating Free Cash Flow | $162.19M | -25.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 31.99 | 21.99 | 19.04 | 14.95 | -59.03% |
| Price to Book | 2.43 | 1.77 | 1.48 | 1.22 | -55.73% |
| Price to Sales | 2.89 | 2.08 | 1.73 | 1.43 | -54.40% |
| Price to Tangible Book Value | -8.13 | -5.94 | -4.58 | -3.77 | -51.50% |
| Price to Free Cash Flow TTM | 19.52 | 15.63 | 13.58 | 11.69 | -47.54% |
| Enterprise Value to EBITDA | 67.69 | 39.24 | 46.51 | 40.22 | -39.42% |
| Free Cash Flow Yield | 5.1% | 6.4% | 7.4% | 8.6% | 90.64% |
| Return on Equity | 8.0% | 8.4% | 8.0% | 8.3% | 6.77% |
| Total Debt | $3.58B | $3.60B | $3.56B | $3.55B | -1.02% |
ICLR earnings call for the period ending September 30, 2021.
ICLR earnings call for the period ending June 30, 2021.
ICLR earnings call for the period ending March 31, 2021.
ICLR earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
